Evidence map›Paper›PMID 39249542›Full record

SynthesisClinical and experimental medicine2024

Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era.

Yan Li, Xinyi Zhang, Zhongqing Zou, Yanqiu Xiong, Xinyuan Gu, Ruiji Zou, Jing Tan, Li Zhang, Yuhuan Zheng, Ting Niu

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical and experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yan LiDepartment of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China.
Xinyi ZhangDepartment of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China.
Zhongqing ZouDepartment of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China.
Yanqiu XiongDepartment of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China.
Xinyuan GuDepartment of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China.
Ruiji ZouDepartment of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China.
Jing TanDepartment of Hematology, Chengdu Third People's Hospital, Chengdu, Sichuan, China.
Li ZhangDepartment of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China. Drzhangli2014@sina.com.
Yuhuan ZhengDepartment of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China. yuhuan_zheng@163.com.
Ting NiuDepartment of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China.

Funding

National Natural Science Foundation of China 82070219
6 · The paper itself

Abstract

The benefit of high-dose melphalan followed by autologous hematopoietic stem cell transplantation (HDM-ASCT) for multiple myeloma (MM) patients with renal insufficiency (RI) is debated. A systematic review and meta-analysis were conducted to assess the safety and efficacy of HDM-ASCT in MM patients with RIs, and the findings were compared with real-world data. The study included 26 articles, 13 of which were pooled for meta-analysis. We compared three different types of MM patients with RI against MM patients with normal renal function (NRF). These patients were: MM patients with RI at the time of transplantation; MM patients with RI at the time of diagnosis; MM patients with RI at diagnosis but with NRF at transplantation. The meta-analysis indicated that MM patients with RIs conditioned with melphalan ≤ 140 mg/m

Indexed as

Hematopoietic Stem Cell TransplantationMelphalanMultiple MyelomaRenal InsufficiencyHumansSurvival AnalysisTransplantation, AutologousTransplantation ConditioningTreatment OutcomeMelphalanAutologous hematopoietic stem cell transplantationMeta-analysisMultiple myelomaRenal insufficiencySystematic review

Identifiers

PMID39249542
PMCPMC11384638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.